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A B S T R A C T
Malignant catarrhal fever (MCF) is a fatal disease of cattle that, in East Africa, follows contact with
wildebeest excreting alcelaphine herpesvirus 1 (AlHV-1). Recently an attenuated vaccine (atAlHV-1) was
tested under experimental challenge on Friesian-Holstein (FH) cattle and gave a vaccine efﬁcacy (VE) of
approximately 90%. However testing under ﬁeld conditions on an East African breed, the shorthorn zebu
cross (SZC), gave a VE of 56% suggesting that FH and SZC cattle may respond differently to the vaccine. To
investigate, a challenge trial was carried out using SZC. Additionally three adjuvant combinations were
tested: (i) Emulsigen1, (ii) bacterial ﬂagellin (FliC) and (iii) Emulsigen1 + bacterial ﬂagellin. We report
100% seroconversion in all immunized cattle. The group inoculated with atAlHV-1 + Emulsigen1 had
signiﬁcantly higher antibody titres than groups inoculated with FliC, the smallest number of animals that
became infected and the fewest fatalities, suggesting this was the most effective combination. A larger
study is required to more accurately determine the protective effect of this regime in SZC. There was an
apparent inhibition of the antibody response in cattle inoculated with atAlHV-1 + FliC, suggesting FliC
might induce an immune suppressive mechanism. The VE in SZC (50–60%) was less than that in FH (80–
90%). We speculate that this might be due to increased risk of disease in vaccinated SZC (suggesting that
the vaccine may be less effective at stimulating an appropriate immune response in this breed) and/or
increased survival in unvaccinated SZC (suggesting that these cattle may have a degree of prior immunity
against infection with AlHV-1).
Crown Copyright ã 2016 Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Malignant catarrhal fever (MCF), an often-fatal disease with a
worldwide distribution, is caused by several g-herpesviruses and* Corresponding author at: School of Veterinary Medicine and Science, University
of Nottingham, Nottingham, UK.
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0378-1135/Crown Copyright ã 2016 Published by Elsevier B.V. This is an open access aaffects many species of even-toed ungulates including cattle, bison
and deer (Russell et al., 2009). The disease ranges from the sporadic
to epidemic and occurs following transmission from an unappar-
ent carrier host to MCF-susceptible species. Deﬁned by the
reservoir species from which the causative virus arises, two major
epidemiological forms of MCF exist, wildebeest-associated (WA-
MCF) (Plowright et al., 1960) and sheep-associated (SA-MCF) MCF
(Reid et al., 1984). The clinical presentation is similar in both forms
with affected animals suffering fever, oral epithelial lesions,
corneal opacities, ocular/nasal discharge and, frequently, death.rticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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auto-destructive pathology resulting in lymphoid hyperplasia and
vasculitis in a range of tissues (Anderson et al., 2008).
WA-MCF occurs primarily in sub-Saharan Africa wherever
wildebeest come into contact with cattle. The causative pathogen,
alcelaphine herpesvirus-1 (AlHV-1), is excreted by wildebeest
calves (Connochaetes taurinus) in the three months following the
brief annual calving period. To avoid disease, pastoralists move
their cattle from wildebeest calving grounds, often to more
marginal land tens of km away, at a time of year when the cattle
condition is most vulnerable. Consequently, the economic costs of
MCF can be signiﬁcant (Lankester et al., 2015). These costs could be
alleviated with the development of an efﬁcacious vaccine.
SA-MCF, caused by ovine herpes virus-2 (OvHV-2) (Hart
et al., 2007), has a worldwide distribution and represents the
more economically signiﬁcant form. Because no in-vitro
propagation system exists for OvHV-2, vaccine development
has focused on AlHV-1, which can be cultured in-vitro. OvHV-2 is
phylogenetically related to AlHV-1 with signiﬁcant DNA se-
quence identity (Hart et al., 2007) and, although the potential for
a vaccine based on AlHV-1 to provide cross-protective immunity
against SA-MCF is likely to be slight (Gailbreath et al., 2010; Taus
et al., 2015), an effective AlHV-1 vaccine may, in addition to
providing beneﬁts to livestock keepers living in proximity with
wildebeest, provide a basis for the development of a protective
vaccine against OvHV-2.
Vaccine development has focused on AlHV-1 and recent United
Kingdom based trials in British Friesian-Holstein (FH) cattle have
demonstrated that, following two inoculations of attenuated
AlHV-1 (atAlHV-1) mixed with the adjuvant Emulsigen1 (MVP
Technologies, 2012), an effective barrier of AlHV-1-neutralizing
antibodies can be induced in the mucosa of the oro-nasal pharynx,
the presumed site for natural infection by the MCF viruses (Haig
et al., 2008; Russell et al., 2012). The vaccine strategy gave FH cattle
approximately 90% protection against AlHV-1 challenge while the
duration of protection was limited to around six months. However
a subsequent ﬁeld trial experiment (Lankester et al., 2016)
indicated that in shorthorn zebu cross (SZC) cattle the level of
protection was only 56% under conditions of natural transmission.
One explanation for the difference in the levels of protection seen
is that FH and SZC cattle may respond differently to the vaccine. To
begin investigating whether such a difference exists, a challenge
trial equivalent to those performed in the UK was repeated on SZC
cattle. The outcome of this trial is reported here.
This challenge trial was also used to investigate whether the
efﬁcacy of the vaccine could be improved by exploiting the
adjuvant properties of particular ligands/agonists for toll-like
receptors (TLR) on immune system cells. TLRs, which form part of
the innate immune system and provide a ﬁrst line of defense
against infection, recognize pathogen-associated molecular pat-
tern molecules (PAMPs) expressed by pathogens but not by
mammalian hosts (Akira and Takeda, 2004; O’Neill et al., 2013). Up
to thirteen TLRs are found in mammals, which recognize microbial
and parasitic components such as unmethylated-CpG DNA
(recognized by TLR9) and bacterial ﬂagellin (recognized by
TLR5). Importantly, engaging TLRs on antigen-presenting cells
can generate inﬂammatory signals that inﬂuence the magnitude
and type of the adaptive immune response that ensues. For this
reason, TLR ligands have been the subject of much recent research
into new generation adjuvants. For example the recombinant
bacterial ﬂagellin monomer (FliC), that is recognized by TLR5, has
demonstrated adjuvant properties for antibody- and cell-mediated
responses in several mammalian and avian species, including
mucosal immune responses (Lee et al., 2015; Taylor et al., 2012).
Therefore we aimed to compare the efﬁcacy of the AlHV-1 vaccine
when combined with one of three different adjuvantcombinations: i) Emulsigen1 alone; ii) FliC alone; or iii) both
adjuvants in combination.
2. Materials and methods
2.1. Ethical approval
The research was carried out with the approval of the
Institutional Animal Care and Use Committee (IACUC) of the
Tanzanian Wildlife Research Institute (TAWIRI), the Commission
for Science and Technology (COSTECH, Tanzania) and the Tanzania
Food and Drug Administration (permit nos. 2011-213-ER-2005-141
and 2012-318-ER-2005-141). All animal experiments were ap-
proved by, and were carried out in strict accordance with, the
University of Nottingham and the Moredun Research Institute’s
experiments and ethics committees and complied with the Home
Ofﬁce of Great Britain and Northern Ireland’s Animals (Scientiﬁc
Procedures) Act 1986 under project license PPL 60/3839. To
minimize suffering, the severity of MCF was not to exceed
moderate (in the progression mild to moderate to severe) as
determined by a clinical scoring system (Russell et al., 2012). As
soon as cattle were determined to have moderate clinical signs
they were euthanized.
2.2. Assessment of FliC efﬁcacy in vitro
To assess the functional response of bovine TLR5 to ligand
stimulation with FliC, the wild type bovine toll-like receptor-5
(boTLR5) was expressed as a protein fusion to Yellow Fluorescent
Protein (YFP) in the plasmid vector pcDNA3-YFP (Metcalfe et al.,
2014). The pcDNA3-YFP-boTLR5 and control pcDNA3-YFP plasmids
were transfected separately into human embryonic kidney cells
(HEK293) using a nucleofector kit (Annexa Biosystems, UK).
Selective pressure was applied by addition of geneticin (G418,
Invitrogen, UK, 600 mg/ml) until stably transfected cell lines were
generated (2–3 weeks). Bovine TLR5 expression was conﬁrmed by
RT-PCR for boTLR5 as described (Metcalfe et al., 2014), ﬂow
cytometry and ﬂuorescence microscopy for YFP. HEK cells
expressing human TLR5 in pcDNA3 (293-htlr5) were used as
control (Invivogen, Toulouse, France).
For the FliC  TLR5 HEK assay, the TLR5+ HEK cells (human and
bovine TLR5) and negative controls were seeded at 2 105 cells per
well in a 24-well plate in 2 ml of Dulbecco’s modiﬁed Eagle’s
medium (DMEM) + 10% FCS and incubated overnight at (37 C, 5%
CO2 in humidiﬁed air). Each cell line was then stimulated with four
concentrations of two preparations of recombinant FliC: i)
Salmonella typhimiurium Flagellin FliC (Enzo Life Sciences, Exeter,
UK) < 0.05 EU/mg endotoxin and ii) as a positive control, endotox-
in-free FliC (tlrl-ﬂic; Invivogen, Source Bioscience LifeSciences,
UK). Cells were stimulated with each of the FliC preparations at 0.1,
0.3, 0.6 and 1 mg/ml and supernatants were collected 24 and 48 h
post stimulation. All treatments were performed in duplicate.
Supernatants (500 ml) were cleared by centrifugation and stored at
20 C. The functional response of bovine and human TLR5 HEK
cells, and control cells, to ligands was measured by their
production of the chemokine CXCL8, using the Quantikine ELISA
measuring human CXCL8 (R&D systems, Abingdon, UK), as
described recently (Willcocks et al., 2013).
2.3. In vivo vaccine trial  animals and virus
Forty clinically healthy Tanzanian shorthorn zebu cross (SZC)
cattle (31 males and 9 females) of approximately six months of age
were purchased from livestock markets in the Simanjiro District in
northern Tanzania. All cattle were immunized against the locally
prevalent and often fatal lymphoproliferative cattle disease East
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given a single treatment against endo- and ectoparasites using
1 ml/50 kg body weight ivermectin (Ivomec1, Merial Animal
Health, Essex, UK) administered by a subcutaneous injection.
Every other week thereafter the cattle were sprayed with the
ectoparasiticide alpha-cypermethrin (Paranex1, Farmbase Ltd, Dar
es salaam, Tanzania), administered at 100 mg/l. All cattle were
ﬁtted with ear tags for identiﬁcation. The cattle were housed at
night in a traditional Maasai boma (corral) and, during the day,
were grazed on community pastureland in the village of Emboreet
(latitude 3.952239, longitude 36.47537).
The strains of the AlHV-1 virus used for vaccination and
challenge were as described previously (Haig et al., 2008; Russell
et al., 2012). Brieﬂy, the virulent AlHV-1 (C500) strain virus was
collected from cultures of bovine turbinate (BT) cells infected with
a cell suspension derived from pooled lymphoid tissue from
rabbits infected with AlHV-1 C500 that had developed MCF.
Infected BT cell cultures were passaged onto fresh BT cells by a 1:4
split four times at peak cytopathic effect (approximately weekly)
after which virulent virus was harvested from culture supernatants
and cells following three rounds of freeze-thaw treatment. Cell-
free virus supernatant was stored at 80 C in batches and
representative aliquots of each batch were titrated to allow
calculation of the appropriate challenge dose. Titration measured
50% tissue-culture-infectious dose (TCID50) as described previous-
ly (Haig et al., 2008; Russell et al., 2012). Pathogenic virus challenge
in this experiment was by intranasal inoculation of 10 ml of virus
suspension with titre approximately 104 TCID50/ml. We were
conﬁdent that this dose would provide a lethal dose in SZC as it
represented 50 x the LD50 virus dose as determined on FH cattle
(Haig et al., 2008). The attenuated AlHV-1 C500 strain, passaged
more than 1000 times, was used as the source of virus for
immunization (Handley et al., 1995). This cell-free virus was
obtained from BT cell culture supernatants, clariﬁed by centrifu-
gation and stored in batches at 80 C. Representative aliquots of
attenuated AlHV-1 (107 TCID50 atAlHV-1) were titrated as
described for virulent AlHV-1.
2.4. Study design
The trial took place between October 2012 and February 2013 at
a time of the year when wildebeest were not calving and had yet to
migrate out of the nearby Tarangire National Park. Natural
exposure to AlHV-1 was therefore deemed unlikely during the
course of the trial. The 40 cattle were randomly assigned to one of
ﬁve experimental groups (n = 8 for each group). Each group was
primed on day zero and boosted on day 28 with an intramuscular
injection in the upper neck with a vaccine mixture as speciﬁed in
Table 1. The group sizes were similar to those described in the two
UK-based immunization experiments upon which this trial was
based (Haig et al., 2008; Russell et al., 2012). On day 77 after the
primary inoculation all animals were challenged with 10 ml of 104
TCID50/ml of virulent AlHV-1 given intranasally. In accordanceTable 1
Immunization treatment groups and inoculations.
Group (n) Primary/Boost immunization (week
1 (8) 107 TCID50 atAlHV-1 in 20% v/v Em
2 (8) 107 TCID50 atAlHV-1 in 1 mg FliC 
3 (8) 107 TCID50 atAlHV-1 in 20% v/v Em
4 (8) 20% v/v Emulsigen1 alone 
5 (8) 1 mg FliC alone 
a at AlHV-1 = attenuated AlHV-1 virus, FliC = ﬂagellin monomer.
b Prime and boost inoculations for each group were identical in composition, given 
c TCID50 = 50% tissue-culture-infectious dose.
d Pathogenic AlHV-1 challenge was given as a 10 ml dose inoculated intranasally.with the previous UK experimental trials, the endpoint of the trial
was three months (90 days) after challenge to allow the
development of MCF in unprotected cattle. As the trial was held
with the cooperation of local Maasai villagers in an area of Tanzania
where MCF was endemic we decided, in recognition of local
sensitivity toward the unnecessary slaughter of cattle, that the
local community would retain all cattle that were healthy at the
endpoint of the trial.
2.5. Sample collection and clinical analyses
Blood was collected in EDTA Vacutainers1 (BD Diagnostics,
New Jersey, USA) from all animals at the day of primary and booster
inoculation, and every two weeks thereafter until the end of the
trial on day 168 (24 weeks after primary inoculation). Nasal
secretion samples were collected using a tampon (Lil-lets1,
regular) inserted into one nostril for 10 min. Following removal,
the tampon was squeezed inside the barrel of a 20 ml syringe and
the extracted nasal secretion collected. Plasma and nasal secretion
samples were frozen at 20 C and, prior to being exported to the
UK for serological analysis, were heat-treated at 56 C for 30 min.
Buffy coat blood cells, also extracted from the uncoagulated blood,
were stored frozen prior to DNA extraction for PCR detection of
viral DNA. Clinical signs were monitored on a daily basis with
animals recorded as ‘healthy’ or, if there was evidence of fever,
excessive ocular/nasal discharge or anorexia, as ‘sick’. Sick animals
were scored using a clinical scoring matrix (Russell et al., 2012)
that ensured euthanasia took place prior to the onset of severe
clinical signs. While histopathology is recognized as the gold
standard for MCF diagnosis, and a post-mortem examination was
carried out on all animals that were euthanized due to onset of
MCF, the tissue samples that were collected were lost in transit to
the UK and could not be analysed. Infection status was therefore
deﬁned based on a combination of clinical signs, analysis of virus-
speciﬁc antibody responses and PCR detection of AlHV-1 DNA.
2.6. Detection of AlHV-1 in blood
Viral DNA was extracted from the frozen buffy coat samples at
the Nelson Mandela African Institution of Science and Technology
(Tanzania) using the ZR Viral DNA KitTM (Zymo Research
Corporation, USA) according to the manufacturer’s instructions.
Viral DNA was assayed by a sensitive, nested PCR as described
previously (Russell et al., 2012) and validated for use in the UK and
Tanzania laboratories. Brieﬂy, following a ﬁrst round of AlHV-1
speciﬁc PCR, performed using AHV-POL1 (50-ggctcataatctatgc-
tactccac-30) and AHV-POL2 (50-attctccacaaactgttttgt-30) primers, a
2 ml aliquot was used for a second hemi-nested round of PCR
performed using AHV-POL internal forward primer (50-ccaaaat-
gaagaccatctta-30), and the ﬁrst-round POL2 as reverse primer. All
PCR reactions were carried out using BIOTAQ DNA polymerase
(Bioline, London, UK  used in Tanzania) or HotStarTaq Plus DNA
polymerase (Qiagen, Hilden, Germany  used in UK). Thermal 0/4)a,b Virus challenge (week 10)c,d
ulsigen1 104 TCID50 AlHV-1
104 TCID50 AlHV-1
ulsigen1 + FliC 104 TCID50 AlHV-1
104 TCID50 AlHV-1
104 TCID50 AlHV-1
as a 1 ml injection intramuscularly to the upper neck region.
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used. Hemi-nested PCR products were analysed by electrophoresis
on 1.8% agarose gel and visualized, photographed and documented
using Bio-Rad Gel DocTM EZ system. AlHV-1 infection status during
the challenge period was classiﬁed as positive if PCR analyses were
positive at any of the three time points assayed (post-challenge day
28, 56 or 86). Although the hemi-nested PCR used here did not
distinguish between vaccine and challenge virus, previous studies
have shown that AlHV-1 DNA was not detected in the blood of any
cattle vaccinated with the attenuated virus, even up to nine
months after vaccination (Russell et al., 2012). Therefore PCR
positive samples from trial cattle were considered to provide
evidence of infection with challenge AlHV-1.
2.7. Analysis of antibody responses by ELISA
1.6.1 To quantify the systemic (plasma) and nasal mucosa total
AlHV-1-speciﬁc and neutralizing antibody responses, a previously
described ELISA and virus neutralization test were used respec-
tively (Russell et al., 2012). ELISA values (difference between means
of positive and negative antigen wells for each sample dilution)
were used to calculate a relative titre for each test sample,
determined with respect to a standard curve of pooled MCF-
positive plasma diluted 1/20 to 1/6000. ELISA titre values have
been expressed as the reciprocal of the calculated end-point
dilution (e.g. 20–6000). All samples were assayed twice using
multiple dilutions. To reduce the likelihood that false positive titres
were counted, any sample that gave a calculated titre of less than
20 (i.e. below the range of the standard curve) was not considered
positive.
2.8. Deﬁnitions of clinical MCF cases
Histopathological analyses were not performed on the post-
mortem tissues of those cattle that did die, nor on the tissues of
cattle that were alive (and were not sacriﬁced) at the end of the
trial. Consequently PCR, antibody responses and clinical signs were
used to determine cases of MCF. Case deﬁnitions were based on
cattle being classiﬁed as symptomatic and on the detection of
AlHV-1 DNA by PCR. In addition, previous studies have shown that
vaccinated cattle that subsequently succumbed to MCF exhibited a
signiﬁcantly increased AlHV-1  speciﬁc antibody titre after
challenge (Haig et al., 2008; Russell et al., 2012). We were therefore
able to use the induction of, or increase in, AlHV-1  speciﬁc
antibody titre following virus challenge as an indication of AlHV-1
infection. The various combinations of diagnostic evidence were
classiﬁed as follows:
 Not infected: Cattle remained asymptomatic, were PCR negative,
survived and, if unvaccinated, had no antibody response
following challenge.
 Fatal AlHV-1 infection: Cattle were PCR positive post-challenge,
had clinical signs compatible with MCF and subsequently
succumbed to disease.
 Non-fatal AlHV-1 infection: Cattle survived and were either PCR
positive post-challenge or showed an induction or increase in
antibody response following challenge.
 Possible AlHV-1 infection: Cattle had clinical signs indicative of
MCF but no PCR or antibody evidence of infection.
These case deﬁnitions allowed further division of cattle into
those for which there was evidence of infection, hereafter termed
‘infected’ (case deﬁnition II and III) and those for which there was
none, hereafter termed ‘uninfected’ (case deﬁnition I). Cases
classiﬁed as deﬁnition IV were termed ‘possibly infected’, based on
clinical signs only.2.9. Vaccine efﬁcacy and comparisons with the other trials
A calculation of vaccine efﬁcacy (for preventing infection) was
performed for the atAlHV-1 + Emulsigen1 formulation (Group 1).
The same calculations were also made for comparison using data
from the Tanzania-based ﬁeld trial (Lankester et al., 2016) and the
UK-based trial (Russell et al., 2012) (hereafter termed Russell), both
of which used Emulsigen1 as an adjuvant, and the UK-based trial
that used Freund’s adjuvant (Haig et al., 2008) (hereafter termed
Haig). The formula is shown in Supporting information 2.
2.10. Statistical analyses
All plots and statistical analyses were made using the R
language for statistical computing (Team, 2013). A t-test was used
to determine if there were differences in the response of HEK cells
expressing TLR5 to FliC ligands. A linear regression model was used
to compare i) the effect that vaccination grouping had on AlHV-1-
speciﬁc antibody titre and ii) the AlHV-1-speciﬁc and neutralizing
antibody titres of vaccinated cattle that were classiﬁed as
‘uninfected’ or ‘infected’. Fisher's Exact Test for Count Data was
used to test the differences in the proportions of cattle in i) each
group that were either ‘uninfected’ or ‘infected’ and ii) the
relationship between prior exposure and survival in control group
cattle. Vaccine efﬁcacy calculations were made using standard
formulae (Orenstein et al., 1985).
3. Results
3.1. FliC stimulates HEK cells transfected with bovine TLR5 in vitro
In a ﬁrst set of experiments, we assessed the response pattern of
HEK cells expressing boTLR5 to different concentrations of FliC
(Fig. 1). Similar to huTLR5, boTLR5 mediated a dose-dependent
response to FliC, as shown by CXCL8 expression, although the
response was signiﬁcantly stronger using HEK cells expressing
huTLR5 (p < 0.02). This is in line with recently published data on
boTLR5 (Metcalfe et al., 2014). The response of HEK cells
transfected with either bovine or human TLR5 to FliC was
signiﬁcantly higher than their respective control cell responses
(p < 0.02 and p < 0.01 respectively for doses >0.1 mg/ml), which did
not respond to either source of FliC. The positive control FliC
(Invivogen) gave similar results to the adjuvant FliC in both cell
types (not shown). Overall, these data conﬁrmed that FliC could be
potentially used as a vaccine adjuvant in the bovine system.
3.2. Emulsigen1, but not FliC supports the development of antibodies
to AIHV-1
To establish baseline values of antibody titres, sera of all 40
animals were tested by ELISA and PCR at the start of the
experiment (day 0). Thirty-eight animals tested negative, whereas
two animals (901 and 926) exhibited low, but positive, AlHV-1-
speciﬁc antibody titres. Four animals (914, 928, 936, 937) showed
evidence of AlHV-1 DNA in blood mononuclear cells by PCR
(Table 2 and Supporting information 1).
Between boosting and challenge, all of the cattle in the atAlHV-
1 vaccinated groups (1, 2 and 3) showed a rise in nasal secretion
AlHV-1-speciﬁc antibody titres, whilst cattle in the atAlHV-1
vaccinated groups 1 and 3 showed a rise in plasma AlHV-1-speciﬁc
antibody titres. Antibody titres peaked between weeks seven and
eight, before declining again. In contrast, none of the cattle in
either adjuvant control group (4 or 5) showed an AlHV-1-speciﬁc
antibody response (Fig. 2). Group 1 had signiﬁcantly higher
geometric mean pre-challenge plasma titres than all other groups
(p < 2  1016, t = 10.4, df = 114), and signiﬁcantly higher nasal
Bovine Human
(A) (B)
0.00
0.25
0.50
0.75
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Fig. 1. FliC efﬁcacy assay: HEK bov (plot A) and HEK hu (plot B) are HEK cells expressing bovine and human TLR5 respectively. HEK bov ctrl and HEK hu ctrl are HEK cells
containing control pcDNA3-YFP plasmid. The HEK bov and HEK hu cell responses to 0.1, 0.3, 0.6 and 1 mg/ml FliC were signiﬁcantly different (p < 0.02). The HEK bov and the
HEK hu cell responses to 0.1, 0.3, 0.6 and 1 mg/ml FliC were signiﬁcantly different from their respective control cell responses (HEK bov ctrl; HEK hu ctrl) (p < 0.02 and p < 0.01
respectively).
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except Group 3. Furthermore, the plasma and nasal secretion titres
of Group 2 were signiﬁcantly lower than those of Groups 1 and 3
(p < 0.001, t = 6.1 (plasma) & t = 5.6 (NS)). Following virus
challenge, geometric mean plasma and nasal secretion AlHV-1-
speciﬁc antibodies increased in all three vaccinated groups, but
error bars were large indicating a wide range of individual
variation. Both control groups also showed a rise in virus-speciﬁc
titre after virus challenge, but these were very low compared to the
immunized groups (Fig. 2).
Regarding AlHV-1  neutralizing antibodies, both control
Groups 4 and 5 remained seronegative, whilst all of the animals
in Groups 1, 2 and 3 seroconverted after the booster immunization
(Fig. 3). Vaccinated Group 2 cattle had signiﬁcantly lower
geometric mean plasma and nasal secretion AlHV-1-neutralizing
antibody titres than both Groups 1 and 3 (p < 0.001, t = 3.4, df = 74
(plasma); p < 0.001, t = 3.5, df = 73 (nasal secretion)).
Blood samples from all cattle were assayed for AlHV-1 DNA at
three post-challenge occasions: week 15, 19 and 23. Where
available, PCR was also performed on terminal blood samples
taken from animals that succumbed to MCF. The results are shown
in Supporting information 1. In Groups 1–5, AlHV-1 virus DNA was
detected in two, four, six, ﬁve and six out of eight cattle,
respectively. The post-challenge PCR status of each animal is
summarized in Table 2.
The details of individual animal and treatment group survival or
acquisition of MCF are shown in Table 2 and are summarized in
Table 3.3.3. Case descriptions
The majority of animals were classiﬁed as either case deﬁnition
(CD) I (not infected) or CD II (fatal AlHV-1 infection), with a small
number of animals (6) showing more complex combinations of
signs (Tables 2 and 3).
In Group 1, two animals succumbed to MCF with clear clinical
signs and detection of virus DNA in the blood post-challenge and
were classiﬁed as CD II. Six animals survived with no clinical signs
and no detection of AlHV-1 DNA in the blood at any time point after
challenge. Of these, one animal (number 913), despite being
asymptomatic and PCR negative, had a rising AlHV-1–speciﬁc
antibody titre following challenge and was classiﬁed as CD III (non-
fatal AlHV-1 infection). The other ﬁve were classiﬁed as CD I.
In Group 2, three animals survived with no clinical signs and no
detection of virus DNA post-challenge and were classiﬁed as CD I.
Four animals succumbed to MCF with clinical signs and virus DNA
in the blood post-challenge and were classiﬁed as CD II. One animal
(number 940) showed clinical signs indicative of MCF and,
although virus DNA was not detected, had a rising AlHV-1
speciﬁc antibody titre in the blood after challenge and was
therefore classiﬁed as CD III.
In Group 3, two animals survived with no clinical signs and no
detection of virus DNA post-challenge and were classiﬁed as CD I.
Six animals succumbed to MCF with clinical signs and virus DNA
detected post-challenge and were classiﬁed as CD II.
In Group 4, four animals succumbed to MCF with clinical signs
and virus DNA detected post-challenge and were classiﬁed as CD II,
while two animals survived with no clinical signs and no detection
of virus DNA in the blood post-challenge. These animals also had
no AlHV-1  speciﬁc antibody response and were classiﬁed as CD I.
Table 2
Summary of the outcomes of the trial.
Group:
vaccination
Cattle ID Baselinea
PCR/Serology
(titre)
Survived/Died (days post challenge)b Clinical signs PCR Antibodyc Case Deﬁnitiond Infection statuse
1:
atAlHV-1 +
Em
903 Survived Healthy Neg reducing I Uninfected
912 Survived Healthy Neg level I Uninfected
913 Survived Healthy Neg rising III Infected
918 Survived Healthy Neg level I Uninfected
923 Died (22) Sick Pos rising II Infected
927 Survived Healthy Neg level I Uninfected
928 Pos Survived Healthy Neg level I Uninfected
930 Died (38) Sick Pos rising II Infected
2:
atAlHV-1 + FliC
906 Survived Healthy Neg level I Uninfected
908 Died (35) Sick Pos rising II Infected
915 Survived Healthy Neg level I Uninfected
925 Died (66) Sick Pos rising II Infected
929 Died (38) Sick Pos rising II Infected
936 Pos Died (56) Sick Pos rising II Infected
938 Survived Healthy Neg level I Uninfected
940 Survived Sick Neg rising III Infected
3:
atAlHV-1 +Em + FliC
905 Died (31) Sick Pos rising II Infected
907 Died (59) Sick Pos rising II Infected
910 Survived Healthy Neg level I Uninfected
916 Died (50) Sick Pos rising II Infected
920 Died (38) Sick Pos rising II Infected
922 Died (38) Sick Pos rising II Infected
924 Died (88) Sick Pos rising II Infected
935 Survived Healthy Neg level I Uninfected
4:
Em only control
904 Died (59) Sick Pos sero-pos II Infected
909 Survived Healthy Neg no titre I Uninfected
914 Pos Survived Sick Pos sero-pos III Infected
917 Died (38) Sick Pos sero-pos II Infected
926 28 Survived Healthy Neg no titre I Uninfected
931 Died (35) Sick Pos sero-pos II Infected
933 Died (35) Sick Pos sero-pos II Infected
937 Pos Survived Sick Neg sero-pos III Infected
5:
FliC only
control
901 35 Died (28) Sick Pos sero-pos II Infected
902 Died (22) Sick Pos sero-pos II Infected
911 Died (31) Sick Pos sero-pos II Infected
919 Survived Sick Neg no titre IV Possibly infected
921 Died (26) Sick Neg no titre IV Possibly infected
932 Died (35) Sick Pos sero-pos II Infected
934 Died (38) Sick Pos sero-pos II Infected
939 Died (38) Sick Pos sero-pos II Infected
a Baseline serology/PCR: animals with AlHV-1-speciﬁc antibodies at day 0 of the experiment (pre-vaccination) are shown by the measured ELISA titre value (cut off value of
20), while animals that had detectable AlHV-1 DNA are indicated as Pos.
b Died: Whether an animal survived or died is indicated, with the number of days that an animal died post-challenge given in parentheses.
c Antibody: summary of plasma ELISA titres post-challenge. For vaccinated animals (Groups 1, 2, 3), ‘rising’ titre after challenge indicates infection with AlHV-1, while for
control animals (Groups 4 and 5), presence of AlHV-1-speciﬁc antibodies (‘sero-pos’) indicates infection with AlHV-1.
d Case deﬁnition: Cases (as described in the text) are deﬁned as I (not infected), II (fatal AlHV-1 infection), III (non-fatal AlHV-1 infection) and IV (possible AlHV-1 infection).
e Infection status: indicated as ‘infected’ for case deﬁnitions (CD) II (fatal AlHV-1 infection) and III (non-fatal AlHV-1 infection); or ‘uninfected’ for cases with CD I (not
infected). Cases classed as CD IV (possible AlHV-1 infection) are indicated as ‘possibly infected’. (atAlHV-1 = attenuated AlHV-1 virus, Em = Emulsigen1, FliC = bacterial
ﬂagellin monomer).
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clinical signs indicative of MCF. Both developed AlHV-1  speciﬁc
antibody responses after challenge but only one had detectable
virus DNA in the blood post-challenge. These were classiﬁed as CD
III.
In Group 5, six animals succumbed to MCF with clinical signs
and virus DNA detected post-challenge and were classiﬁed as CD II.
The remaining two animals (numbers 919 & 921) showed clinical
signs of MCF but neither had virus DNA in the blood post-challenge
nor an AlHV-1  speciﬁc antibody response. One animal died and
the other survived. These were classiﬁed as CD IV (possible AlHV-1
infection). The numbers of each case type per group are
summarized in Table 3.3.4. Comparison of groups
When infection status (‘uninfected’ versus ‘infected’) of Groups
1 and 2 were compared to their respective adjuvant-only control
Groups 4 and 5, the difference in the total number of infected
versus uninfected cases was not signiﬁcant (p = 0.13 and 0.2
respectively). When infection status of Groups 1 & 2 combined
were compared to unvaccinated cattle Groups 4 & 5 combined the
difference in the number of infected cattle was just outside the
conventional threshold of signiﬁcance (p = 0.06). Cattle classiﬁed as
‘possibly infected’ were not included in this analysis. The results
were not substantively different when cattle with evidence of prior
exposure to AlHV-1 were removed. FliC appeared to have a
(A)
(B)
Fig. 3. AlHV-1 – neutralizing antibody titres: The geometric mean AlHV-1 – neutralizing antibody titres (and 95% conﬁdence intervals) in nasal secretion (plot A) and plasma
(plot B) for each of Groups 1–5 are shown (atAlHV-1 = attenuated AlHV-1 virus, Em = Emulsigen1, FliC = ﬂagellin monomer). Group 1, atAlHV-1 + Emulsigen1; Group 2,
atAlHV-1 + FliC; Group 3, atAlHV-1 + Emulsigen1 + FliC; Group 4, Emulsigen1; Group 5, FliC. The primary inoculation occurred in week one, the booster in week four and the
challenge in week eleven.
(A)
(B)
Fig. 2. AlHV-1-speciﬁc antibody titres: The geometric mean nasal secretion (plot A) and plasma (plot B) total AlHV-1  speciﬁc antibody titres (and 95% conﬁdence intervals)
for Groups 1–5 are shown for each sampling time point (atAlHV-1 = attenuated AlHV-1 virus, Em = Emulsigen1, FliC = ﬂagellin monomer, P = primary vaccination, B = booster
vaccination, C = virus challenge and * = PCR assay time-points). Group 1, atAlHV-1 + Emulsigen1; Group 2, atAlHV-1 + FliC; Group 3, atAlHV-1 + Emulsigen1 + FliC; Group 4,
Emulsigen1; Group 5, FliC. The wide conﬁdence intervals after virus challenge (C) indicate large individual variations (see text and Fig. 4).
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Table 3
Summary of case outcomes:.
Groupa Diedb Survivedb MCF casesc
1 (atAlHV-+ Em) ** * 3
2 (atAlHV-+ FliC) **** * 5
3 (atAlHV-+ Em +FliC) ******  6
4 (Em) **** ** 6
5 (FliC) ******& & 6
a atAlHV-1 = attenuated AlHV-1 virus, Em = Emulsigen1, FliC = ﬂagellin monomer.
b  Uninfected: animals with no evidence of MCF infection (CD I). * Infected:
animals with evidence of infection through PCR or virus-speciﬁc antibody response:
CD II, died; CD III, survived. & Possibly infected: Animals with MCF signs only (CD
IV).
c MCF cases (*) equals CD II (Fatal AlHV-1 infection) plus III (Non-fatal AlHV-1
infection).
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and 3) but this effect was not signiﬁcant (p = 0.06).
3.5. The relationship between serological response and protection
We calculated the geometric mean nasal secretion and plasma
AlHV-1-speciﬁc antibody titres for ‘infected’ and ‘uninfected’ cattle
in each group for each time point. The results are illustrated in
Fig. 4. In the pre-challenge titres of infected and uninfected cattle
there were no signiﬁcant differences between any of the groups.
This was also the case with the pre-challenge AlHV-1-neutralizing
antibody titres. In contrast, in Groups 1, 2 and 3, the post-challenge
plasma and nasal secretion titres of ‘infected’ cattle were all
signiﬁcantly higher than ‘uninfected’ cattle (p < 0.04).Fig. 4. AlHV-1 – speciﬁc antibody titres and outcome: The geometric mean nasal secretion
each treatment group according to the outcome following challenge (uninfected = solid
Group 1, atAlHV-1 + Emulsigen1; Group 2, atAlHV-1 + FliC; Group 3, atAlHV-1 + Emulsig3.6. The relationship between prior exposure and survival in control
group cattle
Of the sixteen control group cattle, four had evidence of prior
exposure to AlHV-1 through baseline seropositivity (numbers 901
& 926) or evidence of AlHV-1 DNA in blood mononuclear cells
(numbers 914 & 937). Of these cattle, three survived (numbers 914,
926 & 937) (Table 2). A comparison of the proportions of pre-
exposed and non pre-exposed control group cattle that survived
and died was just outside the conventional level of signiﬁcance
(odds ratio = 11.8; p = 0.06).
3.7. Vaccine efﬁcacy and comparisons with previous trials
An efﬁcacy calculation (for preventing infection) was per-
formed for the formulations used in this trial and the ﬁeld, Russell
and Haig trials. The results, which are shown in Supporting
information 2, indicate that the calculated efﬁcacies in the UK trials
(80–90%) were higher than the Tanzanian trials (50–60%), however
the wide conﬁdence intervals indicate that these differences were
not signiﬁcant. The calculated efﬁcacy of the atAlHV-
1 + Emulsigen1 vaccine formulation following experimental virus
challenge was 50% in this trial in which SZC cattle were used whilst
it was 81.5% in the Russell trial in which FH were used.
4. Discussion
This was the ﬁrst experimental trial to investigate the efﬁcacy of
a new immunization strategy against MCF in an East African breed
of cattle. The vaccine was developed and tested in the UK using FH
cattle and, using the same experimental design (Haig et al., 2008;
Russell et al., 2012), this study was carried out to test its efﬁcacy in (plots A–E) and plasma (plots F–J) AlHV-1 – speciﬁc antibody titres were plotted for
 line; infected = dashed line; P = primary vaccination, B = booster and C = challenge).
en1 + FliC; Group 4, Emulsigen1; Group 5, FliC.
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gated whether the adjuvant FliC improves the protective immune
response.
All tested immunization regimes (Groups 1–3) stimulated
seroconversion in all SZC cattle, generating mucosal (nasal
secretion) and systemic (plasma) AlHV-1-speciﬁc and neutralizing
antibodies. However, comparing immune responses in Groups 1 
3, it is clear that the inclusion of Emulsigen1 was crucial to the
induction of high titre antibody responses and that the use of FliC
did not enhance this response. Despite the 100% seroconversion in
vaccinated cattle, when outcomes were compared between
vaccinated and control groups, the differences were not signiﬁcant.
Nonetheless Group 1 had the highest survival rate (75%), the
smallest number of animals that became infected, and the highest
antibody titres. This suggests that, in SZC cattle, the atAlHV-
1 + Emulsigen1 mixture was the most effective of the tested
formulations.
The pre-challenge antibody titres did not appear to impact
whether an animal became infected or not. This was surprising and
suggests that there are other immunological and/or physiological
factors involved in determining whether an animal becomes
infected. These might include the effective challenge dose
delivered to the correct site of infection; the speciﬁc antigens or
epitopes recognized in protected versus infected cattle; and the
presence of additional subclinical infections at the time of
challenge.
The post-challenge antibody titres were signiﬁcantly higher in
the 14 cattle in Groups 1–3 that became infected than those that
did not. This boosted (anamnestic) response in the infected cattle
indicates that the virus managed to infect these animals,
stimulating memory cells to produce more antibodies. This was
consistent with previous work (Parameswaran et al., 2014; Russell
et al., 2012). As 12 of these cattle died, we conclude that, if the
vaccine fails to protect against infection, any antibody response
that takes place after infection is not protective.
The comparison of vaccine efﬁcacies between the ﬁeld trial
(56%) and this trial (50%) suggests that the mode of challenge did
not greatly affect the efﬁcacy of the vaccine, even though direct
intra-nasal administration of a high virus dose is likely to represent
a more severe challenge than most ﬁeld exposures. Despite no FH
cattle being used in this trial, which makes direct comparison
difﬁcult, the comparison of vaccine efﬁcacies across this study and
the Russell trial allows us to speculate whether the sub-species of
cattle used (Bos taurus (FH) or B. indicus (SZC)) might impact
efﬁcacy. Indeed, the calculated efﬁcacy was 31.5% less when the
vaccine was used in SZC. Vaccine efﬁcacy will decrease following a
reduction in either the number of protected vaccinated animals or
the number of cases in unvaccinated animals. Notably the risk of
vaccinated SZC cattle becoming infected (38%) was more than
double that of FH (17%). This could suggest that the vaccine is not as
effective in SZC at stimulating the appropriate immune response to
protect against AlHV-1 infection. Conversely the risk of unvacci-
nated SZC cattle becoming infected following experimental viral
challenge (75%) was considerably lower than for FH cattle (90%). It
is possible that differences in animal husbandry and the treat-
ments given to the SZC cattle may have contributed to a reduction
in the effectiveness of the viral challenge. It is also possible that,
following repeated annual exposure to migrating wildebeest, the
African breed is more resistant to AlHV-1. This view is supported by
recent genetic studies on the closely-related East African
Shorthorn Zebu, which provide evidence of selection for traits
related to survival in the African environment, including factors
such as resistance to endemic pathogens (Bahbahani et al., 2015;
Murray et al., 2013). Additionally the increased survival of SZC seen
could be the result of natural adaptive immunity following
previous exposure. Indeed, in this trial, post-hoc analysis ofbaseline samples collected before challenge indicated that three of
the ﬁve surviving control group cattle had evidence of a prior
exposure to AlHV-1. Thus previous exposure to MCF virus might
have inﬂuenced the outcome of subsequent infection. This remains
to be addressed experimentally. It is possible that the two animals
that were sero-positive in the pre-trial sample could simply be the
result of infection with viruses that cross-react with the ELISA used
here. While it is likely that other MCF virus infections would induce
cross-reactive antibodies detectable by AlHV-1 ELISA, it has also
been reported that bovine herpesvirus-4 (BoHV-4) antibodies can
detect AlHV-1 infected cells by immunoﬂuorescence (Dewals et al.,
2005). However previous testing did not show cross-reactivity
with BoHV-4 speciﬁc sera in the direct MCF ELISA (Fraser et al.,
2006).
The unexpected survival of control group cattle could also be
related to the effects of the ECF vaccination administered to all
cattle before the trial. Given that both MCF and ECF are associated
with the proliferation of T-cells (Dewals et al., 2008; Kessy and
Matovelo, 2009; Thonur et al., 2006) any non-speciﬁc suppression
of T-cell proliferation as a consequence of ECF vaccination could
provide some protection from MCF pathogenesis. This hypothesis
will be investigated in a subsequent ﬁeld trial.
The vaccine’s efﬁcacy determined by this trial and the ﬁeld trial
is estimated to be 50  56%. Although likely to be too low for
annual vaccination of cattle to replace the traditional MCF
avoidance strategy, a partially protective MCF vaccine could
provide protection to valuable cattle that, because of changes in
land-use, cannot be moved away from oncoming wildebeest.
Furthermore, given there are very few, if any, herpesvirus vaccines
that effectively prevent infection and the establishment of latency,
we consider the proportion of SZC vaccinated animals that did not
become infected in the face of intense challenge in this and the
ﬁeld trial as promising for future vaccine improvement strategies.
We also assessed FliC as an adjuvant. The in-vitro analysis
showed that FliC stimulation of bovine TLR5 induced a signiﬁcant
CXCL-8 response in HEK cells, although this was lower than that
induced via human TLR5. The addition of FliC to the vaccine
formulation (Groups 2 & 3) reduced antibody titres and survival
when compared with Group 1, although this latter effect was just
outside the conventional levels of signiﬁcance (p = 0.06). These
data suggest that FliC is unlikely to enhance protection against
MCF.
WA-MCF has a case-fatality ratio greater than 96% (Plowright
et al., 1960). The ﬁnding that 15% of the trial cattle had evidence of
prior AlHV-1 infection was therefore surprising. Non-fatal
infections have been reported in SA-MCF (Moore et al., 2010;
Otter et al., 2002) and serological evidence of non-fatal infections
was described in the ﬁeld trial (Lankester et al., 2016). These
ﬁndings add further evidence that non-fatal outcomes are a feature
of WA-MCF and that the case-fatality ratio could be lower than
previously described.
The cell biology and pathogenesis of MCF are poorly under-
stood. The fact that four cattle were PCR positive at baseline
suggests that, following initial infection, virus was not eliminated
from cattle that survived the infection. It is not clear whether the
virus became latent, residing in certain body tissues as it does in
the carrier host, nor whether it might cause MCF at a later stage.
In summary, immunization with atAlHV-1 induces an oro-
nasopharyngeal antibody response in FH and SZC and there is
evidence that, when combined with Emulsigen1, the vaccine
mixture induces a partial protective immunity in SZC. A larger
study is required to better quantify this effect. We have shown that
direct challenge with the pathogenic AlHV-1 virus is effective at
inducing MCF in SZC. We have also provided evidence that the
atAlHV-1 + Emulsigen1 formulation may be less effective at
stimulating a protective immune response in SZC cattle than FH
F. Lankester et al. / Veterinary Microbiology 195 (2016) 144–153 153cattle. Furthermore, and in support of the ﬁeld trial, we have
provided evidence that non-fatal AlHV-1 infections are relatively
common and we speculate that there could be resistance to fatal
MCF in SZC cattle, possibly through genetic background, previous
(sub-clinical) exposure to AlHV-1 or alternative acquisition of a
level of inherent immunity. Finally, we demonstrated that FliC is
not an appropriate adjuvant for the atAlHV-1 vaccine.
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